<?xml version="1.0"?>
<metadata xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dc="http://purl.org/dc/elements/1.1/"><dc:title>Establishing a robot-assisted liver surgery program</dc:title><dc:creator>Petrič,	Miha	(Avtor)
	</dc:creator><dc:creator>Nardin,	Živa	(Avtor)
	</dc:creator><dc:creator>Grosek,	Jan	(Avtor)
	</dc:creator><dc:creator>Tomažič,	Aleš	(Avtor)
	</dc:creator><dc:creator>Plešnik,	Boštjan	(Avtor)
	</dc:creator><dc:creator>Trotovšek,	Blaž	(Avtor)
	</dc:creator><dc:subject>robot-assisted surgery</dc:subject><dc:subject>liver surgery</dc:subject><dc:subject>implementation</dc:subject><dc:subject>minimal invasive liver surgery</dc:subject><dc:subject>structured program</dc:subject><dc:description>Background and Objectives: Robot-assisted procedures represent a significant advancement in minimally invasive liver resection techniques. Nonetheless, the introduction of a novel surgical technique in a new environment necessitates meticulous planning and a gradual, stepwise approach. This study describes the adoption of a robotic surgical platform for liver resection at a high-volume tertiary care center. Materials and Methods: We retrospectively analyzed data that had been prospectively collected from fifty robot-assisted liver resections. Descriptive statistics, including frequencies, percentages, means/medians, and standard deviations, were employed for description and summary. Results: The median operative duration was 166 min (range: 85–400 min), with an average intraoperative blood loss of 200 mL (range: 50–1000 milliliters). Intraoperative or postoperative blood transfusion was required in 8% of patients. Conversion to open resection was necessary in one patient (2%). The mean duration of hospitalization was 5 days (range: 3–20 days), with a 30-day readmission rate of 6% and no mortality within 90 days. Postoperative complications classified as Clavien-Dindo grade 3 or higher were observed in five patients (10%). The mean tumor size varied according to pathology: 58.5 mm (range: 30–120 mm) in the hepatocellular carcinoma group; 27.4 mm (range: 10–32 mm) in the secondary malignancy group; and 42.6 mm (range: 24–60 mm) in the intrahepatic cholangiocarcinoma group. The median number of lymph nodes harvested during lymphadenectomy (IHHCA/GBCA) was 5.4, ranging from 1 to 11. The R0 resection rate for malignant tumors was 88.2% (of 30/34). Conclusions: This study validates the safe integration of robot-assisted surgery into liver disease treatment, supported by our initial experience. Despite its technical advantages, robotic-assisted liver surgery remains complex and demanding. Structured robotic training within established programs, meticulous patient selection, and a stepwise implementation approach are critical during the early phases to optimize the outcomes.</dc:description><dc:date>2026</dc:date><dc:date>2025-12-23 08:23:22</dc:date><dc:type>Neznano</dc:type><dc:identifier>24872</dc:identifier><dc:identifier>UDK: 616-089</dc:identifier><dc:identifier>ISSN pri članku: 1648-9144</dc:identifier><dc:identifier>DOI: 10.3390/medicina62010018</dc:identifier><dc:identifier>COBISS_ID: 262651139</dc:identifier><dc:language>sl</dc:language></metadata>
